Nieminen T, Käyhty H, Leroy O, Eskola J
National Public Health Institute, Helsinki, Finland.
Pediatr Infect Dis J. 1999 Sep;18(9):764-72. doi: 10.1097/00006454-199909000-00005.
Our previous studies have shown an antibody-secreting cell (ASC) response to pneumococcal vaccines in adults and suggested that a high IgA ASC response is an indicator of a secretory IgA response in saliva. We believe that the mucosal immune response is potentially an important characteristic of the pneumococcal vaccines and should thus be measured when the new pneumococcal conjugate vaccines are evaluated.
To study mucosal and serum antibody responses to pneumococcal conjugate vaccines in toddlers.
Each investigational vaccine, containing either 3 or 10 microg of pneumococcal PS serotypes 6B, 14, 19F and 23F conjugated to either diphtheria toxoid (PncD) or tetanus protein (PncT), was administered to 10 children (a total of 40 children). The ASC response was measured on Day 7 after immunization by enzyme-linked immunospot assay, and the salivary and serum antibodies were measured before and 7 and 28 days after the immunization by enzyme immunoassay.
The vaccines studied induced ASC responses to the pneumococcal polysaccharides (PS) in all children vaccinated. The ASC responses to the PS components of the vaccine (the geometric mean number of ASCs varying from 120 to 160 ASC/10(6) cells) were lower than those seen earlier in adults after conjugate vaccine (240 to 2015 ASC/10(6) cells), but comparable with those seen earlier in adults after pneumococcal PS vaccine (113 to 136 ASC/10(6) cells). The ASC response was clearly dominated by IgA-secreting cells. Salivary IgA responses were detected in 35% of the children, but IgG was rarely detected in saliva. A positive correlation was demonstrated between the number of IgA ASCs and salivary IgA concentration (r = 0.70, P = 0.01), suggesting that a high number of IgA ASCs after parenteral immunization is an indicator of a secretory IgA response in saliva. On Day 28 after immunization increased serum concentrations of IgG were detected in most vaccinees (75 to 95%, depending on the serotype).
Both mucosal and systemic antibody responses were induced by PncD and PncT vaccines in toddlers.
我们之前的研究显示，成人对肺炎球菌疫苗有抗体分泌细胞（ASC）反应，并表明高IgA ASC反应是唾液中分泌型IgA反应的一个指标。我们认为，黏膜免疫反应可能是肺炎球菌疫苗的一个重要特征，因此在评估新型肺炎球菌结合疫苗时应予以测定。
研究幼儿对肺炎球菌结合疫苗的黏膜和血清抗体反应。
将每种研究用疫苗（含3或10微克与白喉类毒素（PncD）或破伤风蛋白（PncT）结合的肺炎球菌PS血清型6B、14、19F和23F）接种于10名儿童（共40名儿童）。免疫后第7天通过酶联免疫斑点试验测定ASC反应，免疫前以及免疫后7天和28天通过酶免疫测定法测定唾液和血清抗体。
所研究的疫苗在所有接种儿童中均诱导出对肺炎球菌多糖（PS）的ASC反应。疫苗PS成分的ASC反应（ASC的几何平均数为120至160个ASC/百万细胞）低于成人接种结合疫苗后早期所见（240至2015个ASC/百万细胞），但与成人接种肺炎球菌PS疫苗后早期所见（113至136个ASC/百万细胞）相当。ASC反应明显以分泌IgA的细胞为主。35% 的儿童检测到唾液IgA反应，但唾液中很少检测到IgG。IgA ASC数量与唾液IgA浓度之间呈正相关（r = 0.70，P = 0.01），表明经肠外免疫后大量的IgA ASC是唾液中分泌型IgA反应的一个指标。免疫后第28天，大多数接种者（75% 至95%，取决于血清型）血清IgG浓度升高。
PncD和PncT疫苗在幼儿中诱导出黏膜和全身抗体反应。
